My Ironic Journey as an SLP With 'Chemo Brain'

Keyword(s):  
Author(s):  
Samantha Knight ◽  
Daniel Smith ◽  
Carol L. Armstrong
Keyword(s):  

2006 ◽  
Vol 31 (2) ◽  
pp. 129-138 ◽  
Author(s):  
R. B. Raffa ◽  
P. V. Duong ◽  
J. Finney ◽  
D. A. Garber ◽  
L. M. Lam ◽  
...  

2019 ◽  
Vol 8 (2) ◽  
pp. 234 ◽  
Author(s):  
Seonhwa Lee ◽  
Hae-June Lee ◽  
Hyunji Kang ◽  
Eun-Ho Kim ◽  
Young-Cheol Lim ◽  
...  

The authors identified that chemo-brain was induced after trastuzumab (TZB) therapy. In addition, atorvastatin (ATV) could rescue chemo-brain during trastuzumab (TZB) therapy. Enhanced therapeutic effect of TZB was confirmed after ATV therapy. We also investigated that there was no hair loss side effect due to ATV therapy. In an animal model, 150 μg TZB and five serial doses of 20 mg/kg ATV were administered. 18F-fluorodeoxyglucose Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) data were acquired. Statistical parametric mapping analysis and voxel-based morphometry analysis were performed to identify differences in glucose metabolism and gray matter concentration. The enhanced therapeutic efficacy of TZB after ATV treatment was assessed using a human epidermal growth factor receptor 2-positive gastric cancer model. We found a decrease in cerebral glucose metabolism and gray matter concentration in the frontal lobe following TZB therapy (p < 0.005). After subsequent ATV administration, glucose metabolism and regional gray matter concentration were rescued (p < 0.005). Cognitive impairment due to TZB and the rescue effect of ATV were confirmed using a passive avoidance test and quantitative real-time reverse transcription PCR. Furthermore, the penetration and accumulation of TZB in tumors increased by 100% after ATV co-administration, which resulted in an enhanced anti-cancer effect. Our study collectively demonstrates that ATV co-administration with TZB rescued the TZB-induced chemo-brain and enhances the therapeutic efficacy of TZB in tumors. We also showed that there was no hair loss during ATV therapy.


2015 ◽  
Vol 15 (2) ◽  
pp. 87-89 ◽  
Author(s):  
Joyce O. Hislop
Keyword(s):  

Neurology Now ◽  
2008 ◽  
Vol 4 (3) ◽  
pp. 32
Author(s):  
Susan M. Chang
Keyword(s):  

2020 ◽  
Vol 10 (11) ◽  
pp. 851
Author(s):  
Vincent Chin-Hung Chen ◽  
Tung-Yeh Lin ◽  
Dah-Cherng Yeh ◽  
Jyh-Wen Chai ◽  
Jun-Cheng Weng

Breast cancer is the leading cancer among women worldwide, and a high number of breast cancer patients are struggling with psychological and cognitive disorders. In this study, we aim to use machine learning models to discriminate between chemo-brain participants and healthy controls (HCs) using connectomes (connectivity matrices) and topological coefficients. Nineteen female post-chemotherapy breast cancer (BC) survivors and 20 female HCs were recruited for this study. Participants in both groups received resting-state functional magnetic resonance imaging (rs-fMRI) and generalized q-sampling imaging (GQI). Logistic regression (LR), decision tree classifier (CART), and xgboost (XGB) were the models we adopted for classification. In connectome analysis, LR achieved an accuracy of 79.49% with the functional connectomes and an accuracy of 71.05% with the structural connectomes. In the topological coefficient analysis, accuracies of 87.18%, 82.05%, and 83.78% were obtained by the functional global efficiency with CART, the functional global efficiency with XGB, and the structural transitivity with CART, respectively. The areas under the curves (AUCs) were 0.93, 0.94, 0.87, 0.88, and 0.84, respectively. Our study showed the discriminating ability of functional connectomes, structural connectomes, and global efficiency. We hope our findings can contribute to an understanding of the chemo brain and the establishment of a clinical system for tracking chemo brain.


Sign in / Sign up

Export Citation Format

Share Document